Salute e Benessere

Virbac : Declaration of the number of shares and voting rights 07/2025

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers)Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577DateTotal number of shares representing the share capitalTotal number of voting rightsJuly, 31 20258 390 660Gross total of voting rights :...
Nasdaq GlobeNewswire
05/09/2025

Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication

At the median values, two of the AmorphOX powder formulations had a sevenfold increase in plasma values when compared to the oral tablet, although as expected they had lower values than the injectable. In addition to higher exposure than the oral route, the AmorphOX formulations exhibited lower variability in plasma concentration. At the median values, two of the AmorphOX powder formulations had a sevenfold increase in plasma values when compared to the oral tablet, although as expected they...
PR Newswire
05/09/2025

Tiziana Life Sciences Announces Purchase of Shares by Chairman

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, has purchased 25,000 common shares at $1.60 per share, bringing his total holding to 43,277,143 common shares, which is 36.28% of issued share capital. About Foralumab Foralumab, a fully human...
Nasdaq GlobeNewswire
05/09/2025

uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases…

~ All patients in the first cohort achieved between 27- to 208-fold increases in α-Gal A activity relative to mean normal level ~~ All patients in first cohort discontinued enzyme replacement therapy ~~ Preliminary data show AMT-191 has a manageable safety profile at the highest dose ~~ Updated clinical results expected in the first half of 2026 ~ LEXINGTON, Mass. and AMSTERDAM, Sept.05, 2025(GLOBE NEWSWIRE) --uniQureN.V. (NASDAQ: QURE), a leading gene therapy company...
Nasdaq GlobeNewswire
05/09/2025

AAVantgarde presents updated positive clinical data from its AAVB-081 program…

AAVantgarde Bio(AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced the presentation of updated clinical data from the LUCE-1 study at the25th European Society of Retina Specialists (EURETINA) Annual Congress (EURetina 2025), taking place in Paris 4-7 September 2025.Data presented by Prof. Simonelli included safety data for the first 11 participants treated (the 5 participants from the low dose...
Nasdaq GlobeNewswire
05/09/2025

Medical Polymer Market worth $66.29 billion by 2030 - Exclusive Report by…

357 - Tables 357 - Tables 54 - Figures 450 - Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=211635984 Various factors affect the medical polymer market, and it is important to note that they are an indication of advances in the healthcare, materials science, and patient care fields. There is a growing demand for lightweight, durable, and biocompatible materials for medical devices, production of everything from implants to surgical...
PR Newswire
05/09/2025

2025 Ashwagandha Market Analysis Report to 2030 by Mordor Intelligence

Innovation in Convenient Formats Innovation in Convenient Formats Gummies and chews are transforming consumer adoption, growing at over 12% CAGR, as younger demographics and busy professionals favor on-the-go formats. Capsules, tablets, and powders remain significant, while liquid extracts cater to urban wellness markets. Functional Foods & Beverages on the Rise Ashwagandha's integration into teas, protein shakes, and fortified snacks is expanding its consumer base beyond...
PR Newswire
05/09/2025

Midea Redefines Dishwashing at IFA with the Launch of Revolutionary GreenApex…

Complementing this achievement, the TITAN Dishwasher reimagines space utilization and cleaning performance. Through precision engineering—including an 18% leaner pump system—it offers 26% more upper rack capacity within the same elegant footprint. The "Micro-shell, Macro-capacity" design enhance space efficiency while the zone-specific washing system delivers targeted, spotless results. Whether hosting gatherings or enjoying daily meals, users can now rely on TITAN for powerful…
PR Newswire
05/09/2025

Breaking: the SHURUI® Single-Port Surgical Robot Receives its CE Certification

The SHURUI® Single-Port Surgical Robot's unique snake-like instrument technology enables multi-degree of freedom, high-precision operations through a single skin incision, drastically reducing surgical trauma and accelerating patient recovery. Its advanced intelligent motion control and surgeon-friendly interface provide safe, precise, and intuitive operations across complex adult and pediatric procedures. Surgeons can now perform procedures that previously required multiple incisions using just…
PR Newswire
05/09/2025

Czech MedTech Startup Unveils World's First Patented Hydrogen-Based Therapy with…

"This is not another experiment — it is the first technology in the world with the potential to prevent Alzheimer's disease before it even starts, while supporting those already affected," saysDavid Marsalek, founder and CEO ofH2 Global Group. The company believes its effectiveness will be further confirmed in an upcoming new clinical trial. "Our mission is clear: toturn decades of research into real hope for millions of familiesaround the world. We are part of a strong...
PR Newswire
05/09/2025

Glenmark Initiates a Multi-Country Phase 3 Clinical Trial for Envafolimab in…

MUMBAI, India, Sept. 5, 2025 /PRNewswire/ -- Glenmark Pharmaceuticals Ltd., a research-led, global pharmaceutical company, today announced the initiation of a multi-country (ex-China) Phase 3 Clinical Trial for Envafolimab, a novel subcutaneous PD-L1 inhibitor, in patients with resectable Stage III Non-Small Cell Lung Cancer (NSCLC) in the neoadjuvant/adjuvant setting. The Company has received approval from the Drugs Controller General of India (DCGI) to begin patient enrollment and dosing in…
PR Newswire
05/09/2025

GLP-1 Agonists Market to Show Impressive Growth at a CAGR of 10.8% During the…

GLP-1 Agonists Market Summary GLP-1 Agonists Market Summary Discover which indication is expected to grab the major GLP-1 agonists market share @GLP-1 Agonists Market Report Key Factors Driving the Growth of the GLP-1 Agonists Market Rising Prevalence of Type 2 Diabetes and Obesity GLP-1 agonists have emerged as a game-changing therapy for managing obesity and diabetes, offering significant benefits in weight loss and glycemic control. With obesity affecting over650...
PR Newswire
05/09/2025

KingSmith Introduces WalkingCase, a New Generation of Treadmill at IFA Berlin…

KingSmith also introduced two other upcoming innovations. The FC216 Incline Treadmill brings uphill training home with up to 10% automatic incline and KingSmith's patented Vertical Fold for easy, space-saving storage. The three-fold WMX Water and Magnetic Rower combines a bold asymmetric frame with 50 kg adjustable magnetic resistance, delivering powerful, customizable cardio training in a compact design. KingSmith also introduced two other upcoming innovations. TheFC216 Incline Treadmill...
PR Newswire
05/09/2025

SOPHiA GENETICS and Jessa Ziekenhuis Announce Precision Oncology Partnership…

The hospital will implement six SOPHiA GENETICS applications tailored to its testing needs in solid tumors, hematologic malignancies, and liquid biopsy analysis, enhancing both clinical decision-making and research capabilities. The hospital will implement six SOPHiA GENETICS applications tailored to its testing needs in solid tumors, hematologic malignancies, and liquid biopsy analysis, enhancing both clinical decision-making and research capabilities. The SOPHiA GENETICS solution combines...
PR Newswire
05/09/2025

NexLawn Unveils Arm-Equipped Robotic Mowers and Smart Yard Lineup at IFA 2025

The VIDAR and VIDAR AWD Series will launch in Europe and North America in spring 2026. At the exhibition, NexLawn partnered with MOVA to showcase smart yard innovations, with MOVA presenting its gardening tools and NexLawn highlighting its future plans. The VIDAR and VIDAR AWD Series will launch inEuropeandNorth Americain spring 2026. At the exhibition, NexLawn partnered with MOVA to showcase smart yard innovations, with MOVA presenting its gardening tools and NexLawn highlighting its...
PR Newswire
05/09/2025

Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

COPENHAGEN, Denmark, September 5, 2025– Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 3,818,710 as a consequence of employees’ exercise of warrants. The capital increase was effected without any pre-emption rights for the existing shareholders of the Company or others. The shares were subscribed for in cash at the following prices per share of nominally DKK 10: 363,156 shares at DKK 206.82 and 18,715 shares at DKK 190...
Nasdaq GlobeNewswire
05/09/2025

Novo Nordisk to present new semaglutide data on ‘food noise’, body composition…

The INFORM real-world evidence study shows impact of semaglutide on reducing ‘food noise’, and the STEP UP clinical trial highlights semaglutide’s effect on control of eating and body composition after losing weightNext-generation obesity treatment cagrilintide demonstrates promise as standalone therapy (REDEFINE 1); data also being presented on amycretinThe first head-to-head real-world study, REACH shows superiority of Ozempic ®versus dulaglutide on cardiovascular events such as heart...
Nasdaq GlobeNewswire
05/09/2025

Idorsia to collaborate with two leading academic medical centers to launch…

Multi-phase program to standardize treatment, generate real-world evidence and explore AI-powered tools to improve outcomes for hypertension patientsAllschwil, Switzerland & Radnor, Philadelphia – September 5, 2025Idorsia Ltd (SIX: IDIA) announces a first-of-its-kind initiative with the Stanford Hypertension Center and Duke Heart Center to launch IMPACT-HTN, a new three-phase program to transform and modernize the management of difficult-to-control hypertension. Patients requiring...
Nasdaq GlobeNewswire
05/09/2025

Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to…

"This is about creating new options for patients facing some of the toughest cancers," said Jill German, Head of Pathology Lab at Roche Diagnostics. "Our understanding of HER2 is rapidly evolving, and this expanded approval ensures our diagnostics are leading the way. We're enabling clinicians to unlock personalized, life-altering treatments for patients who urgently need them." "This is about creating new options for patients facing some of the toughest cancers,"…
PR Newswire
05/09/2025

Dr Batra's® Brings Specialised XOGEN Advance Treatment to UAE, powered with 36…

Commenting on the launch, Dr.Akshay Batra, Trichologist and Managing Director, Dr Batra's® Healthcare, said: "At Dr Batra's®, we are committed to bringing the world's latest innovations to our patients across the UAE. Hair loss has over 40 causes, from genetics to lifestyle. XOGEN Advance stands out because it not only delivers faster and more effective results but also addresses the root cause with our unique combination of advanced aesthetics and homeopathy. This ensures safe,...
PR Newswire
05/09/2025

New data for Roche's Vabysmo reinforce its efficacy, safety and durability in…

In AVONELLE-X, the largest long-term extension trial in nAMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end 1 Over 60% of people with a difficult-to-treat form of nAMD showed no signs of damaging lesions in the SALWEEN study, and clinically meaningful vision improvements were observed 2 Vabysmo was well tolerated with a consistent long-term safety profile in nAMD in both studies Basel, 05 September...
Nasdaq GlobeNewswire
05/09/2025

Gaucher's Disease Market to Witness Significant Upswing During the Forecast…

Gaucher's Disease Market Summary Gaucher's Disease Market Summary Discover the Gaucher's disease new treatment @New Treatments for Gaucher's Disease Key Factors Driving the Growth of the Gaucher's Disease Market Rising Gaucher's Disease Incidence and Awareness Gaucher's disease, though rare, is the most common lysosomal storage disorder. Its incidence is increasing due to heightened awareness, improved diagnostic capabilities, and the expansion of genetic testing...
PR Newswire
04/09/2025

Inventiva to Participate in Upcoming September Investor Conferences

Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in the following upcoming investor events: H.C. Wainwright 27th Annual Global Investment ConferenceDate:...
Nasdaq GlobeNewswire
04/09/2025

Steven Mickelsen, MD, Launches Del Medtech to Expand Pulsed Field Ablation…

Del Medtech is developing transformative, single-use ablation devices designed to improve efficiency and patient outcomes. With initial focus areas in GI, ENT, men's and women's health, and oncology, the company is targeting market opportunities with annual revenues ranging from $1.4 billion to $7.4 billion and projected growth rates between 9 percent and 13 percent. Del Medtech is developing transformative, single-use ablation devices designed to improve efficiency and patient outcomes...
PR Newswire
04/09/2025
Altri  Comunicati